Sign in
IMAB Stock Price, Chart, Stats & News
I-Mab
Save
I-Mab (IMAB) does not currently pay a dividend.
542.01M
Market cap
–
Current P/E
–
Forward P/E
IMAB chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -18.48% |
ROE | -18.77% |
D/E | 0.02x |
Interest coverage ratio | – |
IMAB valuation
P/E | – |
P/S | – |
P/B | 8.27x |
P/CF | – |
P/FCF | – |
P/OCF | – |
PEG | 0.06x |
EV multiple | -126.46x |
About
I-Mab is a biopharmaceutical company, operating at the clinical stage, dedicated to the discovery, advancement, and commercialization of biologic therapies. Its core mission is to address critical medical needs in both oncology and autoimmune diseases. The company boasts a comprehensive pipeline of drug candidates.
Similar securities
Based on sector and market capitalization
Report issue